International Journal of Cancer Management

Published by: Kowsar

A Comparative Study of Treatment Toxicities Between FOLFOX 4 and Modified FOLFOX 6 in Iranian Colorectal Cancer Patients

Amir Shahram Yousefi Kashi 1 , Abolfazl Razzaghdoust 2 and Afshin Rakhsha 1 , *
Authors Information
1 Department of Radiation Oncology, Shohada-e-Tajrish Hospital, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Cancer Researcher, Department of Radiation Oncology, Shohada-e-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Iranian Journal of Cancer Prevention: January 2017, 10 (1); e9429
  • Published Online: January 23, 2017
  • Article Type: Research Article
  • Received: October 21, 2016
  • Revised: November 6, 2016
  • Accepted: January 3, 2017
  • DOI: 10.17795/ijcp-9429

To Cite: Yousefi Kashi A S, Razzaghdoust A, Rakhsha A. A Comparative Study of Treatment Toxicities Between FOLFOX 4 and Modified FOLFOX 6 in Iranian Colorectal Cancer Patients, Int J Cancer Manag. 2017 ; 10(1):e9429. doi: 10.17795/ijcp-9429.

Abstract
Copyright © 2017, Iranian Journal of Cancer Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1): 9-29[DOI][PubMed]
  • 2. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18(16): 2938-47[DOI][PubMed]
  • 3. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350(23): 2343-51[DOI][PubMed]
  • 4. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009; 27(19): 3109-16[DOI][PubMed]
  • 5. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26(12): 2013-9[DOI][PubMed]
  • 6. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009; 27(5): 663-71[DOI][PubMed]
  • 7. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010; 28(31): 4697-705[DOI][PubMed]
  • 8. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Colangelo LH, Lopa SH, et al. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol. 2009; 27(20): 3385-90[DOI][PubMed]
  • 9. Carlotto A, Hogsett VL, Maiorini EM, Razulis JG, Sonis ST. The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue. Pharmacoeconomics. 2013; 31(9): 753-66[DOI][PubMed]
  • 10. Gibson RJ, Keefe DM, Lalla RV, Bateman E, Blijlevens N, Fijlstra M, et al. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer. 2013; 21(1): 313-26[DOI][PubMed]
  • 11. Comeau JM, Labruzzo Mohundro B. From bench to bedside: promising colon cancer clinical trials. Am J Manag Care. 2013; 19(1 Spec No): 32-7[PubMed]
  • 12. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007; 25(16): 2198-204[DOI][PubMed]
  • 13. Hahemi R, Majidi A, Tabatabaey A, Motamed H. Fatal Disseminated Cryptococcus Infection in an Immunocompetent Patient. Arch Clin Infect Dis. 2014; 9(3)[DOI]
  • 14. Chen Q, Xia HW, Ge XJ, Zhang YC, Tang QL, Bi F. Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. Asian Pac J Cancer Prev. 2013; 14(12): 7421-6[DOI][PubMed]
  • 15. Ramanathan RK, Clark JW, Kemeny NE, Lenz HJ, Gococo KO, Haller DG, et al. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol. 2003; 21(15): 2904-11[DOI][PubMed]
  • 16. Yousefi Kashi AS, Khaledi S, Houshyari M. CT Simulation to Evaluate of Pelvic Lymph Node Coverage in Conventional Radiotherapy Fields Based on Bone and Vessels Landmarks in Prostate Cancer Patients. Iran J Cancer Prev. 2016; 9(3): 6233[DOI][PubMed]
  • 17. Sharif S, O'Connell MJ, Yothers G, Lopa S, Wolmark N. FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest. 2008; 26(9): 956-63[DOI][PubMed]
  • 18. Uncu D, Aksoy S, Cetin B, Yetisyigit T, Ozdemir N, Berk V, et al. Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients. Oncology. 2013; 84(4): 240-5[DOI][PubMed]
  • 19. Rakhsha A, Yousefi Kashi AS, Hoseini SM. Evaluation of Survival and Treatment Toxicity With High-Dose-Rate Brachytherapy With Cobalt 60 in Carcinoma of Cervix. Iran J Cancer Prev. 2015; 8(4): 3573[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments